These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6760862)

  • 1. Piroxicam enhances phagocytosis of Escherichia coli by human polymorphonuclear neutrophils.
    Lingaas E; Midtvedt T
    Biochem Biophys Res Commun; 1982 Nov; 109(1):14-20. PubMed ID: 6760862
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of piroxicam on neutrophil and monocyte-macrophage function.
    Scheinberg MA; Rueda HO; Matheus PC
    Eur J Rheumatol Inflamm; 1983; 6(1):36-40. PubMed ID: 6861812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tenoxicam, a new anti-inflammatory drug, on in vitro neutrophil activation.
    Laghi Pasini F; Capecchi PL; Ceccatelli L; Orrico A; Pasqui AL; Di Perri T
    Boll Chim Farm; 1985 Nov; 124(11):477-82. PubMed ID: 3833264
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro and in vivo effects of piroxicam on rat polymorphonuclear responsiveness after induction of two acute non-specific inflammatory reactions.
    Huy DP; Roch-Arveiller M; Lenoir M; Muntaner O; Thuret A; Giroud JP
    Agents Actions; 1986 Jun; 18(3-4):366-71. PubMed ID: 3019110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro effects of non-steroidal anti-inflammatory drugs on production of oxygen radicals evaluated by the chemiluminescent response of polymorphonuclear leukocytes].
    Mazzullo G; Calabria AA; Lalumera M; Fioravanti A; Bacarelli MR; Pucci G; Renieri A
    Boll Soc Ital Biol Sper; 1985 Aug; 61(8):1193-8. PubMed ID: 4063109
    [No Abstract]   [Full Text] [Related]  

  • 6. Dissociated effect of amphotericin B and desoxycholate on phagocytosis of Escherichia coli by human polymorphonuclear neutrophils.
    Lingaas E; Midtvedt T
    Drugs Exp Clin Res; 1985; 11(11):747-54. PubMed ID: 3915464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of piroxicam on the chemotaxis and random migration of polymorphonuclear leucocytes after induction of immune and non immune inflammations.
    Pham-Huy D; Roch-Arveiller M; Lenoir M; Muntaner O; Giroud JP
    Biomed Pharmacother; 1985; 39(7):381-5. PubMed ID: 2937463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What piroxicam does and why.
    Huskisson EC
    Eur J Rheumatol Inflamm; 1983; 6(1):1-2. PubMed ID: 6407840
    [No Abstract]   [Full Text] [Related]  

  • 9. Second piroxicam symposium.
    Eur J Rheumatol Inflamm; 1983; 6(1):1-138. PubMed ID: 6861808
    [No Abstract]   [Full Text] [Related]  

  • 10. Dissociation by piroxicam of degranulation and superoxide anion generation from decrements in chlortetracycline fluorescence of activated human neutrophils.
    Edelson HS; Kaplan HB; Korchak HM; Smolen JE; Weissmann G
    Biochem Biophys Res Commun; 1982 Jan; 104(1):247-53. PubMed ID: 6280690
    [No Abstract]   [Full Text] [Related]  

  • 11. Propofol inhibits phagocytosis and killing of Staphylococcus aureus and Escherichia coli by polymorphonuclear leukocytes in vitro.
    Krumholz W; Endrass J; Hempelmann G
    Can J Anaesth; 1994 May; 41(5 Pt 1):446-9. PubMed ID: 8055616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for the involvement of human polymorphonuclear leucocyte mannose-like receptors in the phagocytosis of Escherichia coli.
    Rottini G; Cian F; Soranzo MR; Albrigo R; Patriarca P
    FEBS Lett; 1979 Sep; 105(2):307-12. PubMed ID: 385346
    [No Abstract]   [Full Text] [Related]  

  • 13. Superoxide production by polymorphonuclear leucocytes in rheumatoid arthritis and osteoarthritis: in vivo inhibition by the antirheumatic drug piroxicam due to interference with the activation of the NADPH-oxidase.
    Biemond P; Swaak AJ; Penders JM; Beindorff CM; Koster JF
    Ann Rheum Dis; 1986 Mar; 45(3):249-55. PubMed ID: 3006613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The analgetic properties of piroxicam in animals and correlation with experimentally determined plasma levels.
    Milne GM; Twomey TM
    Agents Actions; 1980 Apr; 10(1 Pt 2):31-7. PubMed ID: 7386306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase 1 clinical evaluation of piroxicam].
    Ryumachi; 1980 Jun; 20(3):214-9. PubMed ID: 7414433
    [No Abstract]   [Full Text] [Related]  

  • 16. The effects of isoxicam and piroxicam on renal function in healthy subjects.
    Darragh AS
    Br J Clin Pract; 1985 Apr; 39(4):144-7. PubMed ID: 3940157
    [No Abstract]   [Full Text] [Related]  

  • 17. Modes of action of aspirin-like drugs.
    Abramson S; Korchak H; Ludewig R; Edelson H; Haines K; Levin RI; Herman R; Rider L; Kimmel S; Weissmann G
    Proc Natl Acad Sci U S A; 1985 Nov; 82(21):7227-31. PubMed ID: 2997778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological properties of piroxafos (phosphoric ester of piroxicam)].
    Bianchi A; Amico-Roxas M; Matera M; Mangano O; Trombadore S; Rinaldo G; Caruso A; Puglisi G
    Farmaco Prat; 1982 Aug; 37(8):268-74. PubMed ID: 6982177
    [No Abstract]   [Full Text] [Related]  

  • 19. [Scientific basis of piroxicam (Felden). Pharmacological properties and mechanism of action].
    Wiseman EH
    Wien Med Wochenschr; 1980; 130 Spec No():27-31. PubMed ID: 7456463
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of phagocytosis and killing of bacteria by anaesthetic agents in vitro.
    Krumholz W; Endrass J; Hempelmann G
    Br J Anaesth; 1995 Jul; 75(1):66-70. PubMed ID: 7669473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.